JP2019536740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536740A5 JP2019536740A5 JP2019515905A JP2019515905A JP2019536740A5 JP 2019536740 A5 JP2019536740 A5 JP 2019536740A5 JP 2019515905 A JP2019515905 A JP 2019515905A JP 2019515905 A JP2019515905 A JP 2019515905A JP 2019536740 A5 JP2019536740 A5 JP 2019536740A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- amino acid
- binding
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC[C@]1CC[C@](CN(C(C[C@@]2SCCC(N(C)[C@@](C)C(O[C@@](CC(N(*)c(cc(CC(C)=CC=C[C@]([C@@](C3)(N4)O)OC)cc5OC)c5Cl)=O)[C@]5(C)O[C@]5C[C@]3OC4=O)=O)=O)=O)C2=O)CC1 Chemical compound CC[C@]1CC[C@](CN(C(C[C@@]2SCCC(N(C)[C@@](C)C(O[C@@](CC(N(*)c(cc(CC(C)=CC=C[C@]([C@@](C3)(N4)O)OC)cc5OC)c5Cl)=O)[C@]5(C)O[C@]5C[C@]3OC4=O)=O)=O)=O)C2=O)CC1 0.000 description 1
- PLNMJXBWNJMINP-UHFFFAOYSA-N O=C(CC1)N(CC2CCCCC2)C1=O Chemical compound O=C(CC1)N(CC2CCCCC2)C1=O PLNMJXBWNJMINP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662399249P | 2016-09-23 | 2016-09-23 | |
| US62/399,249 | 2016-09-23 | ||
| US201762558711P | 2017-09-14 | 2017-09-14 | |
| US62/558,711 | 2017-09-14 | ||
| PCT/US2017/053113 WO2018067331A1 (en) | 2016-09-23 | 2017-09-22 | Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536740A JP2019536740A (ja) | 2019-12-19 |
| JP2019536740A5 true JP2019536740A5 (OSRAM) | 2020-11-05 |
| JP7066691B2 JP7066691B2 (ja) | 2022-05-13 |
Family
ID=60083442
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515905A Active JP7066691B2 (ja) | 2016-09-23 | 2017-09-22 | 二重特異性抗ｍｕｃ１６－ｃｄ３抗体および抗ｍｕｃ１６薬物複合体 |
| JP2019515904A Active JP7066690B2 (ja) | 2016-09-23 | 2017-09-22 | 抗ｍｕｃ１６（ムチン１６）抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515904A Active JP7066690B2 (ja) | 2016-09-23 | 2017-09-22 | 抗ｍｕｃ１６（ムチン１６）抗体 |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10738130B2 (OSRAM) |
| EP (3) | EP3515946B1 (OSRAM) |
| JP (2) | JP7066691B2 (OSRAM) |
| KR (2) | KR102531251B1 (OSRAM) |
| CN (2) | CN110036032B (OSRAM) |
| AU (2) | AU2017331363B2 (OSRAM) |
| BR (2) | BR112019005670A2 (OSRAM) |
| CA (2) | CA3037738A1 (OSRAM) |
| CL (4) | CL2019000712A1 (OSRAM) |
| CO (1) | CO2019003967A2 (OSRAM) |
| DK (2) | DK3515487T5 (OSRAM) |
| ES (2) | ES2952735T3 (OSRAM) |
| FI (1) | FI3515487T3 (OSRAM) |
| HR (2) | HRP20231281T1 (OSRAM) |
| HU (2) | HUE063020T2 (OSRAM) |
| IL (2) | IL265369B2 (OSRAM) |
| LT (2) | LT3515487T (OSRAM) |
| MD (1) | MD3515487T2 (OSRAM) |
| MX (2) | MX2019003322A (OSRAM) |
| MY (2) | MY200230A (OSRAM) |
| NZ (2) | NZ751907A (OSRAM) |
| PH (2) | PH12019500550A1 (OSRAM) |
| PL (2) | PL3515487T3 (OSRAM) |
| PT (2) | PT3515487T (OSRAM) |
| RS (2) | RS64691B1 (OSRAM) |
| SI (2) | SI3515487T1 (OSRAM) |
| SM (2) | SMT202200359T1 (OSRAM) |
| WO (2) | WO2018058003A1 (OSRAM) |
| ZA (2) | ZA201901557B (OSRAM) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP3277725B1 (en) | 2015-03-30 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| CN108290951B (zh) * | 2015-09-23 | 2022-04-01 | 瑞泽恩制药公司 | 优化抗cd3双特异性抗体和其用途 |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| LT3411404T (lt) | 2016-02-03 | 2022-12-27 | Amgen Research (Munich) Gmbh | Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai |
| RS64691B1 (sr) * | 2016-09-23 | 2023-11-30 | Regeneron Pharma | Bispecifična anti-muc16-cd3 antitela i konjugati anti-muc16 sa lekom |
| BR112019016336A2 (pt) * | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| RU2747095C2 (ru) * | 2018-05-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) | Мономолекулярный химерный т-клеточный рецептор к раковому антигену са125 |
| CN108659131B (zh) * | 2018-05-28 | 2021-09-14 | 长春力太生物技术有限公司 | 一种抗ceacam-5的单域抗体及其应用 |
| US11548947B2 (en) | 2018-06-21 | 2023-01-10 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof |
| TWI890661B (zh) * | 2018-06-21 | 2025-07-21 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 |
| MD3823665T2 (ro) | 2018-07-19 | 2024-05-31 | Regeneron Pharma | Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| EA202190601A1 (ru) * | 2018-08-23 | 2021-07-14 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕ |
| RS66543B1 (sr) | 2018-08-31 | 2025-03-31 | Regeneron Pharma | Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela |
| EP4270009A3 (en) | 2018-10-31 | 2024-01-17 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
| EA202191058A1 (ru) * | 2018-11-16 | 2021-10-07 | Мемориал Слоун Кеттеринг Кэнсер Сентр | Антитела против муцина-16 и способы их применения |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| JP7588586B2 (ja) * | 2018-12-19 | 2024-11-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性抗ｍｕｃ１６×抗ｃｄ２８抗体およびその使用 |
| JP7637052B2 (ja) | 2018-12-19 | 2025-02-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性抗ｃｄ２８ｘ抗ｃｄ２２抗体及びその使用 |
| EP3941941A1 (en) | 2019-03-22 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
| JP7675016B2 (ja) * | 2019-05-08 | 2025-05-12 | メモリアル スローン ケタリング キャンサー センター | ムチン－１６に対するヒト化抗体およびそれを使用する方法 |
| WO2020256721A1 (en) * | 2019-06-19 | 2020-12-24 | Synthis, Llc | Antib0dy-alk5 inhibitor conjugates and their uses |
| KR20220024035A (ko) * | 2019-06-21 | 2022-03-03 | 리제너론 파마슈티칼스 인코포레이티드 | Muc16 및 cd3에 결합하는 이중 특이적 항원 결합 분자와 4-1bb 공동 자극의 병용 |
| WO2021005607A1 (en) * | 2019-07-09 | 2021-01-14 | National Institute For Biotechnology In The Negev Ltd. | Antibodies with reduced immunogenicity |
| JP7629906B2 (ja) * | 2019-08-15 | 2025-02-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞標的化のための多重特異性抗原結合分子およびそれらの使用 |
| TW202108631A (zh) * | 2019-08-21 | 2021-03-01 | 大陸商和鉑醫藥（上海）有限責任公司 | 一種抗ｃｄ４７抗原結合蛋白及其應用 |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| JP2022548197A (ja) | 2019-12-06 | 2022-11-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｖｅｇｆタンパク質組成物及びその製造方法 |
| EP4069373A1 (en) * | 2019-12-06 | 2022-10-12 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CN115803009A (zh) | 2020-05-08 | 2023-03-14 | 瑞泽恩制药公司 | 用于治疗眼病和癌症的vegf阱和微阱及方法 |
| JP2024502234A (ja) * | 2020-12-22 | 2024-01-18 | アムジエン・インコーポレーテツド | 抗ｃｄ３含有分子の拡散勾配アッセイ |
| HRP20250696T1 (hr) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | Sastavi i postupci za liječenje sindroma oslobađanja citokina |
| TW202304507A (zh) * | 2021-04-02 | 2023-02-01 | 美商再生元醫藥公司 | 含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物 |
| US12275798B2 (en) | 2021-06-17 | 2025-04-15 | Boehringer Ingelheim International Gmbh | Tri-specific binding molecules |
| AU2022398486A1 (en) | 2021-11-24 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies |
| EP4460520A1 (en) | 2022-01-07 | 2024-11-13 | Regeneron Pharmaceuticals, Inc. | Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| CN118829652A (zh) * | 2022-01-10 | 2024-10-22 | 再生元制药公司 | Muc16嵌合抗原受体 |
| EP4464722A1 (en) * | 2022-01-10 | 2024-11-20 | Nanjing Leads Biolabs Co., Ltd. | Antibody and use thereof |
| IL315405A (en) | 2022-03-17 | 2024-11-01 | Regeneron Pharma | Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies |
| WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2024051752A1 (en) * | 2022-09-06 | 2024-03-14 | I-Mab Biopharma Co., Ltd. | Multispecific constructs and uses thereof |
| US20250076310A1 (en) | 2022-12-08 | 2025-03-06 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
| KR20250151441A (ko) | 2023-02-17 | 2025-10-21 | 리제너론 파마슈티칼스 인코포레이티드 | Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포 |
| TW202500582A (zh) | 2023-03-13 | 2025-01-01 | 美商再生元醫藥公司 | 以雙特異性抗cd22x抗cd28分子治療癌症之方法 |
| WO2024258870A2 (en) | 2023-06-12 | 2024-12-19 | Amgen Inc. | Lymphotoxin beta receptor agonist binding proteins |
| WO2025014913A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Bispecific pd-l1xcd28 antibodies and methods of use thereof |
| TW202519547A (zh) | 2023-07-10 | 2025-05-16 | 美商再生元醫藥公司 | 雙特異性PD-L1x4-1BB抗體及其使用方法 |
| WO2025036848A1 (en) | 2023-08-11 | 2025-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Anti-muc16 antibodies and uses thereof |
| CN117024596B (zh) * | 2023-08-18 | 2024-02-27 | 镜像绮点(上海)细胞技术有限公司 | 肿瘤原代细胞特异性标记与活体成像 |
| US20250114469A1 (en) | 2023-10-09 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE |
| CN119978126A (zh) * | 2023-11-10 | 2025-05-13 | 深圳市菲鹏生物治疗股份有限公司 | 抗muc16抗体、靶向muc16的嵌合抗原受体及其应用 |
| TW202523694A (zh) * | 2023-11-17 | 2025-06-16 | 中國大陸商上海藥明生物技術有限公司 | 抗muc16抗體及其用途 |
| WO2025117869A1 (en) | 2023-11-29 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Methods of treating recurrent ovarian cancer and endometrial cancer with bispecific anti-muc16 x anti-cd28 antibodies in combination with anti-pd-1 antibodies or bispecific anti-muc16 x anti-cd3 antibodies |
| WO2025128652A1 (en) | 2023-12-12 | 2025-06-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating endometrial cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| AU2002254615A1 (en) | 2001-04-17 | 2002-10-28 | The Board Of Trustees Of The University Of Arkansas | Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |
| DE50105971D1 (de) | 2001-12-04 | 2005-05-25 | Brahms Ag | Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 125 |
| KR20050083774A (ko) | 2002-10-16 | 2005-08-26 | 유로-셀티크 소시에떼 아노뉨 | 세포-연관된 ｃａ 125/ｏ772ｐ에 결합하는 항체들 및그것의 용도의 방법들 |
| CA2523716C (en) | 2003-05-31 | 2014-11-25 | Micromet Ag | Human anti-human cd3 binding molecules |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| CL2008001334A1 (es) * | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| EP3561513A1 (en) | 2007-05-23 | 2019-10-30 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| US8187801B2 (en) | 2008-04-24 | 2012-05-29 | Wisconsin Alumni Research Foundation | Methods and kits to detect and monitor ovarian cancer and preeclampsia |
| BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
| JP5622117B2 (ja) | 2008-07-21 | 2014-11-12 | ポリテリクスリミテッド | 生体分子を接合するための新規な試薬及び方法 |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EP2549276B1 (en) | 2009-08-10 | 2015-02-25 | UCL Business PLC | Reversible covalent linkage of functional molecules |
| SMT201900372T1 (it) | 2010-02-08 | 2019-09-09 | Regeneron Pharma | Topo con catena leggera comune |
| ES2621874T3 (es) | 2010-03-26 | 2017-07-05 | Memorial Sloan-Kettering Cancer Center | Anticuerpos para MUC16 y métodos de uso de los mismos |
| US20110256157A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| EP2642979A4 (en) * | 2010-11-26 | 2014-09-17 | Univ Witwatersrand Jhb | PHARMACEUTICAL COMPOSITION |
| ES2898854T3 (es) | 2011-05-27 | 2022-03-09 | Ambrx Inc | Composiciones que contienen, métodos que implican, y usos de derivados de dolastatina enlazados con aminoácidos no naturales |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| JP6393617B2 (ja) | 2011-10-14 | 2018-09-19 | シアトル ジェネティクス，インコーポレーテッド | ピロロベンゾジアゼピンおよび標的コンジュゲート |
| WO2013053872A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| CA2850103C (en) | 2011-10-14 | 2019-09-10 | Spirogen Sarl | Pyrrolobenzodiazepines |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| BR112014013526A8 (pt) | 2011-12-05 | 2017-06-13 | Igenica Biotherapeutics Inc | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| KR102306490B1 (ko) | 2013-03-15 | 2021-09-28 | 리제너론 파아마슈티컬스, 인크. | 생물학적 활성 분자, 그의 접합체 및 치료 용도 |
| SG11201601230RA (en) | 2013-08-26 | 2016-03-30 | Regeneron Pharma | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| KR102357961B1 (ko) * | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MX391249B (es) * | 2015-03-17 | 2025-03-21 | Memorial Sloan Kettering Cancer Center | Anticuerpos anti-muc16 y sus usos. |
| CN107995912A (zh) | 2015-03-27 | 2018-05-04 | 里珍纳龙药品有限公司 | 美登素类衍生物、其偶联物和使用方法 |
| CN108290951B (zh) * | 2015-09-23 | 2022-04-01 | 瑞泽恩制药公司 | 优化抗cd3双特异性抗体和其用途 |
| RS64691B1 (sr) | 2016-09-23 | 2023-11-30 | Regeneron Pharma | Bispecifična anti-muc16-cd3 antitela i konjugati anti-muc16 sa lekom |
-
2017
- 2017-09-22 RS RS20230945A patent/RS64691B1/sr unknown
- 2017-09-22 DK DK17784089.9T patent/DK3515487T5/da active
- 2017-09-22 HR HRP20231281TT patent/HRP20231281T1/hr unknown
- 2017-09-22 JP JP2019515905A patent/JP7066691B2/ja active Active
- 2017-09-22 SM SM20220359T patent/SMT202200359T1/it unknown
- 2017-09-22 HU HUE17784089A patent/HUE063020T2/hu unknown
- 2017-09-22 WO PCT/US2017/053114 patent/WO2018058003A1/en not_active Ceased
- 2017-09-22 AU AU2017331363A patent/AU2017331363B2/en active Active
- 2017-09-22 PL PL17784089.9T patent/PL3515487T3/pl unknown
- 2017-09-22 SI SI201731387T patent/SI3515487T1/sl unknown
- 2017-09-22 MY MYPI2019001374A patent/MY200230A/en unknown
- 2017-09-22 BR BR112019005670A patent/BR112019005670A2/pt unknown
- 2017-09-22 SM SM20230308T patent/SMT202300308T1/it unknown
- 2017-09-22 MY MYPI2019001357A patent/MY194596A/en unknown
- 2017-09-22 PL PL17787989.7T patent/PL3515946T3/pl unknown
- 2017-09-22 EP EP17787989.7A patent/EP3515946B1/en active Active
- 2017-09-22 AU AU2017339711A patent/AU2017339711B2/en active Active
- 2017-09-22 SI SI201731189T patent/SI3515946T1/sl unknown
- 2017-09-22 NZ NZ751907A patent/NZ751907A/en unknown
- 2017-09-22 KR KR1020197010783A patent/KR102531251B1/ko active Active
- 2017-09-22 CA CA3037738A patent/CA3037738A1/en active Pending
- 2017-09-22 IL IL265369A patent/IL265369B2/en unknown
- 2017-09-22 MX MX2019003322A patent/MX2019003322A/es unknown
- 2017-09-22 DK DK17787989.7T patent/DK3515946T5/da active
- 2017-09-22 PT PT177840899T patent/PT3515487T/pt unknown
- 2017-09-22 JP JP2019515904A patent/JP7066690B2/ja active Active
- 2017-09-22 EP EP23182446.7A patent/EP4273172A3/en active Pending
- 2017-09-22 LT LTEPPCT/US2017/053113T patent/LT3515487T/lt unknown
- 2017-09-22 LT LTEPPCT/US2017/053114T patent/LT3515946T/lt unknown
- 2017-09-22 ES ES17784089T patent/ES2952735T3/es active Active
- 2017-09-22 MD MDE20190826T patent/MD3515487T2/ro unknown
- 2017-09-22 BR BR112019005697A patent/BR112019005697A2/pt unknown
- 2017-09-22 KR KR1020197011419A patent/KR102418667B1/ko active Active
- 2017-09-22 RS RS20220906A patent/RS63660B1/sr unknown
- 2017-09-22 MX MX2019003326A patent/MX2019003326A/es unknown
- 2017-09-22 IL IL265309A patent/IL265309B2/en unknown
- 2017-09-22 ES ES17787989T patent/ES2925563T3/es active Active
- 2017-09-22 CA CA3037536A patent/CA3037536A1/en active Pending
- 2017-09-22 US US15/713,574 patent/US10738130B2/en active Active
- 2017-09-22 PT PT177879897T patent/PT3515946T/pt unknown
- 2017-09-22 CN CN201780071820.1A patent/CN110036032B/zh active Active
- 2017-09-22 NZ NZ751903A patent/NZ751903A/en unknown
- 2017-09-22 FI FIEP17784089.9T patent/FI3515487T3/fi active
- 2017-09-22 HR HRP20221202TT patent/HRP20221202T1/hr unknown
- 2017-09-22 CN CN201780067123.9A patent/CN110214026B/zh active Active
- 2017-09-22 WO PCT/US2017/053113 patent/WO2018067331A1/en not_active Ceased
- 2017-09-22 US US15/713,578 patent/US10941208B2/en active Active
- 2017-09-22 HU HUE17787989A patent/HUE059761T2/hu unknown
- 2017-09-22 EP EP17784089.9A patent/EP3515487B1/en active Active
-
2019
- 2019-03-13 ZA ZA2019/01557A patent/ZA201901557B/en unknown
- 2019-03-14 ZA ZA2019/01591A patent/ZA201901591B/en unknown
- 2019-03-14 PH PH12019500550A patent/PH12019500550A1/en unknown
- 2019-03-19 PH PH12019500604A patent/PH12019500604A1/en unknown
- 2019-03-19 CL CL2019000712A patent/CL2019000712A1/es unknown
- 2019-03-20 CL CL2019000726A patent/CL2019000726A1/es unknown
- 2019-04-22 CO CONC2019/0003967A patent/CO2019003967A2/es unknown
-
2020
- 2020-06-26 US US16/913,154 patent/US11485793B2/en active Active
-
2021
- 2021-10-08 CL CL2021002645A patent/CL2021002645A1/es unknown
-
2022
- 2022-09-26 US US17/953,114 patent/US20230272111A1/en active Pending
-
2023
- 2023-09-08 CL CL2023002690A patent/CL2023002690A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536740A5 (OSRAM) | ||
| JP2019532056A5 (OSRAM) | ||
| JP2025111463A5 (OSRAM) | ||
| JP6800853B2 (ja) | 抗ｃ１０ｏｒｆ５４抗体およびその使用 | |
| JP6010241B2 (ja) | Ｄｌｌ３モジュレーター及び使用方法 | |
| JP2019146572A5 (OSRAM) | ||
| JP2017535257A5 (OSRAM) | ||
| WO2020102779A1 (en) | MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF | |
| TW202330036A (zh) | 抗體-藥物結合物之製造方法 | |
| US20190218304A1 (en) | Potentiating the effect of atp release | |
| KR20160097336A (ko) | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 | |
| JP2017535246A5 (OSRAM) | ||
| KR20160037130A (ko) | 신규한 항체 접합체 및 이의 용도 | |
| JP2017510559A5 (OSRAM) | ||
| JP2012522513A5 (OSRAM) | ||
| CN107074950A (zh) | 使用抗nkg2a抗体的治疗方案 | |
| RU2015110632A (ru) | Молекулы, связывающиеся с 4-1вв | |
| KR20170010764A (ko) | 신규한 항-ｒｎｆ43 항체 및 사용 방법 | |
| JP2020501598A5 (OSRAM) | ||
| JPWO2019224711A5 (OSRAM) | ||
| KR20170045351A (ko) | 신규한 항-mfi2 항체 및 사용 방법 | |
| FI3773738T3 (fi) | Vasta-aine-lääkekonjugaatteja ja niiden käyttöjä syövän hoitamiseksi | |
| JP7264831B2 (ja) | 抗ｇｌｏｂｏ ｈ抗体を含有する抗体－薬物コンジュゲートおよびその使用 | |
| JP2014515600A5 (OSRAM) | ||
| JPWO2022087243A5 (OSRAM) |